One To Watch

NervGen Pharma

A clinical-stage biotech developing neuroreparative therapies intended to promote nervous system repair after injury and in select neurologic diseases. Its lead program, NVG-291, is being evaluated in spinal cord injury.

Headquarters and Global Presence

NervGen is based in Vancouver, British Columbia, and runs North America–led clinical development with U.S. trial sites.

Founding and History

NervGen was established to advance therapeutics aimed at enabling repair in the central nervous system by addressing biologic mechanisms that limit regeneration after injury. In January 2026, the company began trading on Nasdaq under ticker NGEN, while maintaining its TSX Venture listing.

Therapy Areas and Focus

NervGen’s disclosed focus is neurotrauma and neurology, with development centered on:

Spinal cord injury
Additional neurologic indications where impaired neural repair is a core feature (program selection and timing remain development-stage dependent)

Technology Platforms and Modalities

NervGen’s lead modality is a peptide therapeutic designed to modulate inhibitory pathways associated with chondroitin sulfate proteoglycans (CSPGs), which are implicated in limiting neural repair following CNS injury. The company’s approach is positioned around functional recovery endpoints and objective neurophysiology measures in clinical development.

Programs and Clinical Pipeline

NVG-291

Modality: peptide
Lead indication: spinal cord injury
Development stage: Phase I b/II a (CONNECT SCI study), with separate cohorts in chronic and subacute spinal cord injury

Other programs

NervGen has disclosed earlier-stage work on additional candidates (including NVG-300) in preclinical evaluation across nervous system injury and disease models.

Key Personnel

Adam Rogers, MD, President and Chief Executive Officer (appointed February 9, 2026)
Bill Adams, Chief Financial Officer
Daniel Mikol, MD, PhD, Chief Medical Officer

Strategic Positioning

NervGen’s near-term strategy is execution-driven: advancing NVG-291 through controlled studies in spinal cord injury, defining a registrational pathway with regulators, and building the clinical and operational evidence required to support pivotal trial design.

FAQ Section

NervGen is developing therapies intended to enable functional recovery by reducing biologic inhibition of neural repair after CNS injury. Its lead approach targets CSPG-associated inhibitory signaling as a mechanism linked to impaired regeneration and recovery.

The company’s primary clinical focus is spinal cord injury, with broader stated interest in other neurotraumatic and neurologic conditions where restoring function would require meaningful neural repair.

The lead clinical asset is NVG-291 in spinal cord injury (Phase I b/II a). The company has also referenced additional earlier-stage candidates, including NVG-300, in preclinical evaluation.

Recent developments include:

February 2026: the board appointed Adam Rogers as President and Chief Executive Officer, effective immediately
January 2026: NervGen began trading on Nasdaq (ticker NGEN)
July 2025: the company announced a leadership transition concurrent with its reporting of topline results from the chronic cohort of its CONNECT SCI study

NervGen has reported topline results from the chronic spinal cord injury cohort of its Phase I b/II a CONNECT SCI study, including achievement of a primary endpoint and directional improvements across functional assessments. The company has indicated ongoing analysis and continued enrollment in the subacute cohort.

The main milestones are tied to:

Continued enrollment and results from the subacute cohort of CONNECT SCI
Regulatory alignment on a registrational pathway and pivotal trial design in spinal cord injury
Transition into a pivotal program if supported by the full Phase I b/II a dataset and regulatory feedback

NervGen is positioned around a neuroreparative mechanism intended to improve functional outcomes rather than symptomatic management. Competitive differentiation will be determined by reproducibility of functional signals across cohorts, safety/tolerability, and the feasibility of executing a registrational trial with clinically meaningful endpoints.

Want to Update your Company's Profile?